Candel Therapeutics, Inc. (CADL) earnings date

Nasdaq · Small cap · EDGAR filings

Email me when this date changes · free account, one click to stop

How this company behaves

Announces its report date Not enough announcements on file yet to say
Reports after the quarter ends 44 days, typically, give or take 13 (last 8 releases)

Last 8 releases

PeriodReleasedTimingDays after period endFiling
Q3 FY2026Thu, Nov 12, 2026after close 43 8-K
Q2 FY2026Thu, Aug 13, 2026before open 44 8-K
Q1 FY2026Thu, May 14, 2026before open 44 8-K
Q4 FY2025Thu, Mar 12, 2026before open 71 8-K
Q3 FY2025Thu, Nov 13, 2025before open 44 8-K
Q2 FY2025Thu, Aug 14, 2025before open 45 8-K
Q1 FY2025Tue, May 13, 2025before open 43 8-K
Q4 FY2024Thu, Mar 13, 2025after close 72 8-K

What they guided beta

Q3 FY2026 "Cash and cash equivalents of $203.1 million, as of September 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q2 2028." exhibit
Q3 FY2026 "Based on current operating plans, the Company expects that its existing cash and cash equivalents, as of September 30, 2026, will be sufficient to fund operations into Q2 2028." exhibit
Q2 FY2026 "Cash and cash equivalents of $201.6 million, as of June 30, 2026, are expected to be sufficient to fund the Company’s current operating plan into Q1 2028, which includes activities to support the potential commercial launch of aglatimagene in 2027 NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the second quarter ended June 30, 2026, and provided a corpo" exhibit
Q2 FY2026 "The Company expects to present potential long-term survival data from arm C of its phase 1b clinical trial of linoserpaturev in patients with recurrent high-grade glioma (rHGG) in Q4 2026." exhibit
Q2 FY2026 "Based on current operating plans, the Company expects that its existing cash and cash equivalents, as of June 30, 2026, will be sufficient to fund operations into Q1 2028." exhibit

Get this as JSON

curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/next/CADL
# how far back the record goes for this company
curl -H "X-API-Key: vt_live_..." https://api.veritasdata.dev/v1/coverage/CADL

Put this date on your page

A badge that stays current. It links back to this page and needs no key. Embed it unmodified, with its link to this page intact: the badge is too small to carry the notice below, so the page it links to does.

Read by software from public filings and company announcements. Can be wrong. Verify with the company or the SEC. Not investment advice.

CADL earnings date badge

HTML

<a href="https://veritasdata.dev/company/CADL/"><img src="https://veritasdata.dev/embed/CADL.svg" alt="CADL earnings date" width="240" height="56"></a>

Markdown

[![CADL earnings date](https://veritasdata.dev/embed/CADL.svg)](https://veritasdata.dev/company/CADL/)

Script

<script async src="https://veritasdata.dev/embed/CADL.js"></script>

Get a free key: 100 calls, every company

Sign in with GitHub or Google. The key works on every endpoint and in the MCP server.

curl -H "X-API-Key: vt_live_..." "https://api.veritasdata.dev/v1/next/CADL"

Dates come only from SEC EDGAR and company announcements. Nothing here is investment advice.